论文部分内容阅读
目的 :观察胎肝活细胞悬液在原发性肝癌肝动脉介入化疗栓塞 (TACE)中的作用及疗效。方法 :5 6例TACE中随机分为A组 2 9例 ,B组 2 7例 ,A组加入胎肝活细胞悬液输注 ,2 5 0ml/次 ,1～ 2次 /周 ,连用 2月。结果 :近期有效率A、B组分别为6 2 0 6 %和 5 5 5 6 % (P >0 0 5 ) ;栓塞后综合征发生率A组为 13 79% ,B组 5 1 85 % (P <0 0 1) ;Karnofsk评分≥ 80分 ,A组79 3 1% ,B组 44 44% (P <0 0 1) ;肝衰的发生率B组 3 7%。术后一周肝功能child分级 ,A级 :A组与B组分别为 75 86 %和3 7 0 3 % (P <0 0 5 ) ;3年生存率A组为 44 82 % ,B组 14 81% (P <0 0 5 )。结论 :TACE加用胎肝活细胞悬液减少肝功能衰竭的发生 ,发挥协同抗癌作用 ,提高患者生活质量 ,提高患者的 3年生存率
Objective : To observe the role and therapeutic effect of fetal liver viable cell suspension in hepatic artery interventional chemoembolization (TACE) of primary hepatic carcinoma. METHODS: Fifty-six patients with TACE were randomly divided into A group (n = 29) and group B (n = 27). Group A was injected with a suspension of fetal liver suspension (250ml/time, 1-2 times per week for 2 months). . Results: The effective rates in the recent A and B groups were 6 2 0 6 % and 5 55 6 % respectively (P > 0 05); the incidence of postembolism syndrome was 13 79% in group A and 5 1 85% in group B ( P <0 0 1); Karnofsk score ≥ 80 points, A group 79 3 1%, B group 44 44% (P <0 01); The incidence of liver failure in group B was 37%. After one week of liver function, the child grading was grade A: group A and group B were 758.6% and 379.0%, respectively (P<0.05); the 3-year survival rate was 44.82% in group A and 14 group B. % (P < 0 0 5 ). Conclusion : TACE plus fetal liver cell suspension reduces the occurrence of hepatic failure, exerts a synergistic anti-cancer effect, improves the patient’s quality of life, and improves the patient’s 3-year survival rate.